Archives  Mitochondria and Oxidative Stress: Pathogenetic Mechanisms in Parkinson’s Disease
This issue features the second of 2 articles on the pathogenetic mechanisms of Parkinson’s disease (PD). Other articles include reviews on gene therapy trials in PD patients, research that reveals a significant role B cells play in the pathogenesis of multiple sclerosis (MS), and evidence linking Epstein-Barr virus and the development of MS. The Highlights section summarizes several articles published recently in the literature.
Parents, Pesticides, and Proteins: Pathogenetic Mechanisms of Parkinson’s Disease
This issue features the first of two articles on recent research into the pathogenesis of PD. Other articles include a comprehensive update on recent clinical trials in MS as well as a critique of clinical trial design in general and in MS in particular. The Highlights section reviews several significant research articles in the recent neurology literature.
Advanced Imaging Techniques and MS Pathology
A structural-functional anomaly found in MS is the poor correlation between CNS lesion burden as revealed by conventional MRI and the degree of clinical disability. Magnetic resonance techniques are therefore being modified to allow for more precise analyses of biologic markers of neuronal function that could enable better correlations between CNS damage and functional loss in MS. This will lead to a more precise definition of therapeutic efficacy. Read on for more on this and other topics covered in this issue.
Parasitism and Multiple Sclerosis Risk
Parasites avoid immune attack by altering the activity of the immune system. Some of these alterations have been found to counteract the activities of cells involved in immune-mediated diseases such as multiple sclerosis (MS). Understanding how the presence of parasites and how immunomodulator therapies alleviate MS symptoms appear to be converging on potential mechanisms that may ultimately affect treatment strategies in MS.
Experimental Autoimmune Encephalomyelitis and MS Drug Development
Experimental autoimmune encephalomyelitis (EAE)—a syndrome that has many pathogenetic and pathophysiologic similarities to multiple sclerosis (MS)—refers to a series of models of human diseases. This issue of Neura will present the experimental and clinical foundations of development of MS therapies based on efficacy in EAE. Also included in this issue is a report on the link between low cholesterol and Parkinson’s disease (PD) and how the use of statins may increase the risk, a report on the molecular biology of Huntington’s disease, and a Highlights From the Literature section providing 3 synopses of current neurological research.
Issues in PPMS
Patients with primary–progressive multiple sclerosis (PPMS)—an estimated 10% to 15% of the MS population—experience unremitting neurologic decline, without the acute attacks and frequent recovery that occur in most MS patients with relapsing–remitting MS (RRMS). This issue of Neura will review the diagnostic, clinical, therapeutic, and other issues unique to PPMS. Also included in this issue is a report on vitamin D level and the risk of MS, a report on the implication of ergot-derived dopamine agonists used to treat Parkinson’s disease in the development of valvular heart damage, and an article discussing fatigue in MS.
Saving the Neuron-Part 2
Saving the Neuron-Part 1
Our 3-part series on neurodegeneration and neuroprotection begins with this issue of Neura: Perspectives on CNS Disease Management. Also included are overviews on current and prospective treatments to manage Parkinson’s disease (PD) and the long-term efficacy and safety of the therapies available to treat multiple sclerosis (MS).
The Immune System and Its Role in MS-Part 3
The final installment of our series on the immune system and its role in multiple sclerosis (MS) is featured in this issue. Also included is a primer on Huntington’s disease, patient information on Medicare Part D, and a review of recently published literature.
The Immune System and Its Role in MS-Part 2
The 3-part series on the immune system as it relates to multiple sclerosis (MS) continues with a focus on the antigen-specific immunity. Articles on pregnancy in MS and statins and their use in diseases of the central nervous system (CNS) are also found in this issue.
The Immune System and Its Role in MS-Part 1
Although the exact cause of multiple sclerosis (MS) is yet unidentified, many specialists believe that immune system dysfunction may be an important factor in disease onset and progression. The first article of the Winter 2005 issue examines innate and acquired immunity as the first in a 3-part series on the immune system. This issue also reviews amyotrophic lateral sclerosis, surveys some of the complementary and alternative treatments that many MS patients have tried, and summarizes new literature on MS and Parkinson's disease.
Neura Special Edition: State of the Art Multiple Sclerosis Treatment
The Fall 2005 Neura Special Edition includes 3 succinct articles on multiple sclerosis (MS) and its treatment, including expert commentary from the Neura Editorial Board's roundtable discussion.
Fall 2005
Diseases of the central nervous system can be difficult to diagnose and treat because of the similarities in the symptoms and individualized responses to medications. This edition of Neura takes a broad look at diagnostic issues in both Parkinson’s disease and multiple sclerosis, and describes genetic factors that may contribute to the future of personalized medicine.
Spring 2005
Diagnosis and management of diseases of the central nervous system (CNS) can be difficult but may be aided by knowledge of the genetic predispositions to disease and the existence of accurate diagnostic criteria. This issue of Neura features stories related to the mysteries of CNS diseases—Parkinson’s disease (PD) and multiple sclerosis (MS) in particular—and how scientific research and clinical studies are providing fresh clues toward solving the puzzles they present and toward the development of safe and effective therapies.
Winter 2004
Worldwide population growth and rapid globalization allow zoonoses to become less localized. An article in this issue of Neura focuses on some of the viral encephalitides, such as West Nile virus, that appear to be zoonoses that leaped to humans and that may constitute emerging threats to public health. The issue also covers potential new drugs and treatment strategies for multiple sclerosis (MS) as well as quality of life (QoL) issues affecting patients with Parkinson's disease (PD).
Fall 2004
By one recent count, as many as 66 experimental agents for Alzheimer’s disease (AD) have reached the clinical trial phase. This issue of Neura identifies some of the more promising agents and drug classes for the treatment of AD. Also featured are articles on symptom management in multiple sclerosis and treatment of levodopa-induced motor fluctuations in Parkinson’s disease (PD).
Summer 2004
This issue provides a primer on human prion diseases, such as bovine spongiform encephalopathy, or mad cow disease, and updated information on the possible role for vitamin D supplementation in the prevention and treatment of multiple sclerosis. It also compares potential neuroprotection interventions for patients with Parkinson’s disease.
Spring 2004
This issue focuses on the use of magnetic resonance imaging (MRI) to predict future conversion of patients with a clinically isolated syndrome to clinically definite multiple sclerosis (MS). It also provides updated information on the use of postmarketing surveillance of drug safety and reviews the use of cannabis and cannabinoids in neurological disease.
Winter 2003
This issue highlights three topics pertinent to common neurological conditions: managed care initiatives currently used for cost containment in Alzheimer's disease (AD), education programs to help patients cope with chronic neurological disease, and the possible link between infectious agents and multiple sclerosis (MS).
Fall 2003
This issue begins with the second parts of articles on imaging techniques in neurological disease begun in the last issue: one describing conventional and experimental applications of magnetic resonance imaging (MRI) and another discussing the use of magnetic resonance spectroscopy (MRS). This issue also covers pregnancy in women with multiple scleorsis (MS) and current data on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent Alzheimer's disease.
Summer 2003
This issue begins with the first parts of articles on imaging techniques in neurological disease: one describing conventional and experimental applications of magnetic resonance imaging (MRI) and another discussing the use of magnetic resonance spectroscopy (MRS). This issue also covers neurotrophic growth factors and managed care cost-containment measures in multiple sclerosis (MS).
Spring 2003
This issue reviews updated information on the measurement of brain atrophy in Alzheimer's disease (AD), the treatment of multiple sclerosis (MS)—related fatigue, research into neuroprotection to slow progression of neurodegenerative diseases, and the mechanisms of action of current MS therapies.
Fall 2002
Neura’s third issue ranges widely across the health care field: from an introduction to the Health Insurance Portability and Accountability Act (HIPAA) and its implications for those in clinical practice through an analysis of some of the special circumstances that can compromise treatment adherence in multiple sclerosis to a report on the emerging science of pharmacogenomics. The editors give a glimpse of some of the critical issues affecting medical practice today.
Spring 2002
The spring 2002 issue focuses on the clinical measurement of multiple sclerosis. Reviewed are the various scales used to measure disease progression, disability, and the role of relapse. Also explored is the use of magnetic resonance imaging to monitor central nervous system disease and how well these findings correlate with patients’ disease status and activity. This issue also contains a “Nurse Corner.”
Winter 2001
The inaugural issue of Neura: Perspectives on CNS Disease Management focuses on multiple sclerosis (MS). It begins with a review of the pathophysiology and natural history of the disease. Next, the approved immunomodulatory treatments are reviewed and there is an interview with Dr. Corey C. Ford, who discusses current perspectives in the use of magnetic resonance imaging in MS. Finally, Neura introduces 3 regular features: “Patient tear-out,” an educational tool to improve the dialogue between patient and neurologist; “Highlights From the Literature,” a synopsis of recent contributions to the neurology literature; and “Meetings,” a calendar of upcoming neurology conferences and Web resources.
|
|
